Related Experiment Video
Updated: Jan 13, 2026

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.1K
Antidiabetic Potential of Mangiferin: An In Silico and In Vivo Approach
Anna Vesnina1,2, Violeta Le1, Svetlana Ivanova2,3
1Laboratory of Natural Nutraceuticals Biotesting, Kemerovo State University, Kemerovo 650043, Russia.
Pharmaceutics
|October 29, 2025
Summary
Mangiferin, predicted to prevent diabetes, showed pro-inflammatory effects in vivo, not anti-inflammatory or hypoglycemic activity. Further studies are needed to explore lower doses and bioavailability for potential therapeutic benefits.
Area of Science:
- Pharmacology
- Biochemistry
- In silico and in vivo studies
Background:
- Mangiferin is a plant compound with predicted antidiabetic properties based on in silico analysis.
- Published data suggests mangiferin's potential in preventing diabetes mellitus.
- This study aimed to validate these predictions through empirical in vivo testing.
Purpose of the Study:
- To obtain in vivo evidence for the biological activity of mangiferin, particularly its anti-inflammatory, antidiabetic, and hypocholesterolemic effects.
- To compare in vivo results with in silico predictions for mangiferin's antiglycation activity.
- To investigate the effects of mangiferin on inflammation, glucose levels, and cholesterol in animal models.
Main Methods:
- In silico prediction using the IT Microcosm system identified potential biotargets (MAPK10, HCAR2, CALCRL) for mangiferin's activity.
- In vivo anti-inflammatory activity was assessed in Sprague-Dawley rats with induced acute and chronic inflammation.
- Hypoglycemic and hypocholesterolemic activities were evaluated in Sprague-Dawley rats and Mus musculus mice, respectively, using alloxan-induced diabetes and Kolliphor P 407-induced hypercholesterolemia models.
Main Results:
- In vivo studies indicated that mangiferin exhibited pro-inflammatory activity.
- Mangiferin did not significantly affect fasting body weight, blood glucose, or serum cholesterol concentrations in the tested models.
- The empirical findings contradicted the in silico predictions of antidiabetic and anti-inflammatory properties.
Conclusions:
- There is a discrepancy between the in silico predicted biological activities of mangiferin and the observed in vivo effects.
- Mangiferin demonstrated pro-inflammatory rather than anti-inflammatory or hypoglycemic effects in this study.
- Further research is recommended, focusing on lower mangiferin doses and strategies to enhance its bioavailability to reconcile predicted and actual activities.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
521
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581

